Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and Baseline Characteristics.
García-Pérez LE, Boye KS, Rosilio M, Jung H, Heitmann E, Norrbacka K, Federici MO, Gentilella R, Guerci B, Giorgino F, Aigner U, Sapin H. García-Pérez LE, et al. Among authors: heitmann e. Diabetes Ther. 2021 Jul;12(7):1929-1946. doi: 10.1007/s13300-021-01076-0. Epub 2021 Jun 7. Diabetes Ther. 2021. PMID: 34097244 Free PMC article.
Weight loss in patients with type 2 diabetes receiving once-weekly dulaglutide plus insulin lispro or insulin glargine plus insulin lispro: A post-hoc analysis of the AWARD-4 study across baseline body mass index subgroups.
Fuechtenbusch M, Aberle J, Heitmann E, Nicolay C, Jung H. Fuechtenbusch M, et al. Among authors: heitmann e. Diabetes Obes Metab. 2019 Jun;21(6):1340-1348. doi: 10.1111/dom.13658. Epub 2019 Mar 15. Diabetes Obes Metab. 2019. PMID: 30737891 Clinical Trial.
The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Baseline Patient-Reported Outcomes.
Boye KS, Sapin H, García-Pérez LE, Rosilio M, Orsini Federici M, Heitmann E, Jung H, Aigner U, Guerci B, Giorgino F, Norrbacka K. Boye KS, et al. Among authors: heitmann e. Diabetes Ther. 2020 Oct;11(10):2383-2399. doi: 10.1007/s13300-020-00908-9. Epub 2020 Sep 3. Diabetes Ther. 2020. PMID: 32880876 Free PMC article.
The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Patients with Type 2 Diabetes (TROPHIES): Patient disposition, clinical characteristics and treatment persistence at 12 months.
Guerci B, Giorgino F, Sapin H, Boye K, Lebrec J, Federici MO, Heitmann E, Dib A, Füchtenbusch M, García-Pérez LE. Guerci B, et al. Among authors: heitmann e. Diabetes Obes Metab. 2022 Dec;24(12):2373-2382. doi: 10.1111/dom.14823. Epub 2022 Aug 31. Diabetes Obes Metab. 2022. PMID: 35876235 Free PMC article.
Clinical characteristics, treatment patterns, and persistence in individuals with type 2 diabetes initiating a glucagon-like peptide-1 receptor agonist: A retrospective analysis of the Diabetes Prospective Follow-Up Registry.
Jung H, Tittel SR, Schloot NC, Heitmann E, Otto T, Lebrec J, Pavel M, Lanzinger S. Jung H, et al. Among authors: heitmann e. Diabetes Obes Metab. 2023 Jul;25(7):1813-1822. doi: 10.1111/dom.15038. Epub 2023 Mar 23. Diabetes Obes Metab. 2023. PMID: 36855221
The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in patients with type 2 diabetes (TROPHIES): Final, 24-month analysis of time to first significant treatment change, treatment persistence and clinical outcomes.
Giorgino F, Guerci B, Füchtenbusch M, Lebrec J, Boye K, Orsini Federici M, Heitmann E, Dib A, Yu M, Sapin H, García-Pérez LE. Giorgino F, et al. Among authors: heitmann e. Diabetes Obes Metab. 2023 Dec;25(12):3465-3477. doi: 10.1111/dom.15244. Epub 2023 Sep 12. Diabetes Obes Metab. 2023. PMID: 37700627
The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Final patient-reported outcomes at 24 months.
Boye KS, Lebrec J, Dib A, Heitmann E, Federici MO, Yu M, Sapin H, Barrett A, Guerci B, Giorgino F, Füchtenbusch M, García-Pérez LE. Boye KS, et al. Among authors: heitmann e. Diabetes Obes Metab. 2023 Dec;25(12):3453-3464. doi: 10.1111/dom.15145. Epub 2023 Sep 15. Diabetes Obes Metab. 2023. PMID: 37712754
The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in type 2 diabetes patients (TROPHIES): resource use and costs of treatment in clinical practice in France, Germany, and Italy.
Barrett A, Boye KS, García-Pérez LE, Giorgino F, Guerci B, Füchtenbusch M, Yu M, Sapin H, Dib A, Heitmann E, Federici MO, Lebrec J. Barrett A, et al. Among authors: heitmann e. J Med Econ. 2024 Jan-Dec;27(1):866-879. doi: 10.1080/13696998.2024.2367919. Epub 2024 Jul 4. J Med Econ. 2024. PMID: 38963346 Free article.
Immunization of pigs with replication-incompetent adenovirus-vectored African swine fever virus multi-antigens induced humoral immune responses but no protection following contact challenge.
Zajac MD, Trujillo JD, Yao J, Kumar R, Sangewar N, Lokhandwala S, Sang H, Mallen K, McCall J, Burton L, Kumar D, Heitmann E, Burnum T, Waghela SD, Almes K, Richt J, Kim T, Mwangi W. Zajac MD, et al. Among authors: heitmann e. Front Vet Sci. 2023 Jun 19;10:1208275. doi: 10.3389/fvets.2023.1208275. eCollection 2023. Front Vet Sci. 2023. PMID: 37404778 Free PMC article.
30 results